Sodium-glucose co-transporters (SGLTs) have a key role in the re-absorption of 
glucose in the kidneys. Therefore, inhibition of SGLTs may provide a novel 
therapeutic strategy for diabetes mellitus. SGLT2 inhibitors enhance renal 
glucose excretion by inhibiting renal glucose re-absorption and reduce plasma 
glucose level, as well as they decrease the body weight. Their action is insulin 
independent and they improve insulin resistance in diabetes mellitus. Numerous 
SGLT2 inhibitors have been developed and evaluated in clinical trials. Phase III 
trials are needed to assess the safety of SGLT2 inhibitors. Results suggest that 
the beneficial effects of SGLT2 inhibition might be achieved without the 
development of significant side effects.